Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Painkillers little help against dementia
Hopes that painkillers might help stave off Alzheimer's disease were dampened by a large new study. Pfizer's Celebrex and the over-the-counter Aleve didn't benefit thinking skills as researchers had hypothesized. "These were not the results we were hoping for," one of the co-authors said. "We designed this study hoping we would see a protective effect of these drugs." They'll continue monitoring the participants to see if a delayed benefit crops up.
Previous studies had shown that people who took the drugs ran a lower risk of developing Alzheimer's, but those studies weren't designed specifically for that purpose. It's a bummer for Pfizer and Bayer (which makes Aleve), because proof of Alzheimer's prevention would translate into a big new use for those meds. "Unfortunately, as this paper demonstrates, research doesn't always translate into successful new treatments," a philosophical Dr. Gail Cawkwell of Pfizer told the LA Times.
- read the Times article
Related Article:
Big pharma sees big payback for Alzheimer's research
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage


